Jan de Backer – CEO, Fluidda
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Address: Groeningenlei 132
2550 Kontich
Groeningenlei 132, 2550 Kontich,Belgium
Tel: +32 3 450 87 20
FluidDA acts as a CRO to support the implementation of the FluidDA imaging biomarkers into clinical trials and clinical practice. To offer a high quality service, FluidDA employs experts in all required fields from medical doctors to biomedical scientists and engineers. A complete package is offered to manage a study from design to (scientific) reporting.
FluidDA has experience in pulmonology, respiratory drug delivery, sleep medicine, maxillofacial surgery and cardiovascular. The company collects stores, manages and analyzes data coming from a variety of imaging modalities such as CT, MRI, Cone Beam CT, SPECT and ultrasound. From clinical studies, FluidDA has gained extensive experience in scanning protocols to achieve proper image quality. FluidDA can write or assist in writing protocols for clinical imaging studies according to GCP guidelines as well as analyzing and writing of study results in international peer reviewed journals.
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the…
The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains…
The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President…
Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA…
To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment.…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
The EMA’s Pre-Accession Assistance Program (IPA) helps EU candidate and potential candidate countries align their medicines regulations with EU standards through training, capacity-building, and policy support. As a new op-ed…
The European Brain Council (EBC) is a key player in advancing brain health research and policy across Europe, bringing together diverse voices to address the pressing issues of neurological and…
James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe. In…
Last year the European Commission (EC) came out with a proposal to reform the EU’s core pharmaceutical legislation, aiming to address affordability, accessibility, and availability, among other objectives. One of…
Vikas Krishan, chief digital business officer at the global data and digital engineering solutions firm Altimetrik, outlines the implications of the European Union’s forthcoming AI Act for the pharma industry…
See our Cookie Privacy Policy Here
